What is the Cancer Tumor Profiling market size?

The Cancer Tumor Profiling market size is approximately USD 1.2 billion as of 2023.

What are the key drivers of the Cancer Tumor Profiling market?

Key drivers include increasing cancer incidence, rising demand for personalized medicine, and growing adoption of precision medicine.

What are the major challenges facing the Cancer Tumor Profiling market?

Challenges include high costs, complex regulatory frameworks, and limited awareness of tumor profiling benefits.

Which regions are leading the Cancer Tumor Profiling market?

North America and Europe are currently leading the market, due to strong healthcare infrastructure and high adoption rates.

Who are the top companies in the Cancer Tumor Profiling market?

Top companies include Illumina, Thermo Fisher Scientific, and Roche, which offer a range of tumor profiling solutions.

What future opportunities exist in the Cancer Tumor Profiling market?

Future opportunities include emerging markets, increasing use of liquid biopsies, and growing demand for non-invasive tumor profiling.

How is technology impacting the Cancer Tumor Profiling market?

Advances in next-generation sequencing, artificial intelligence, and machine learning are driving market growth and improving tumor profiling accuracy.

What is the current regulatory landscape for the Cancer Tumor Profiling market?

The regulatory landscape is evolving, with increasing focus on precision medicine, genomic testing, and data privacy, driving the need for compliance and standardization.

What is the future outlook for the Cancer Tumor Profiling market?

The future outlook is positive, with growing demand for tumor profiling driving market growth and innovation, and expected to reach USD 2.5 billion by 2033.

Cancer (Tumor) Profiling Growth Drivers & Forecast Analysis 2033

Cancer (Tumor) Profiling by Application (Clinical, Research), by Types (Immunoassay, NGS, Mass Spectrometry, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Cancer (Tumor) Profiling Market Size | CAGR 10.2 Forecast 2033

Cancer (Tumor) Profiling Growth Drivers & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cancer (Tumor) Profiling Market Overview

The Cancer (Tumor) Profiling market refers to the process of analyzing tumors to identify genetic mutations and understand the biology of cancer. As the Cancer (Tumor) Profiling market size is estimated to be around $13.9 billion, the growth outlook for this industry is promising, with a market forecast indicating a compound annual growth rate (CAGR) of 13.8% during the forecast period from 2026 to 2033. The industry expansion is driven by increasing demand for personalized medicine, advancements in technology, and rising incidence of cancer. The scope of this market encompasses various synonyms such as tumor profiling, cancer genomics, and precision medicine.

Loading chart…

The growth forecast for the Cancer (Tumor) Profiling market is driven by several key forces, including technology shifts such as next-generation sequencing, regulations supporting the use of precision medicine, and changing consumer behavior towards personalized healthcare. The largest region in this market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be shaped by increasing competition, advancements in artificial intelligence, and the need for data analytics to interpret complex genomic data. As the market continues to evolve, it is essential for C-suite, strategic planners, and business development teams to stay informed about the latest trends and developments in the Cancer (Tumor) Profiling market.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Qiagen; Neogenomics Laboratories; HTG Molecular Diagnostics; Genomic Health; Caris Life Sciences; Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Cancer (Tumor) Profiling market is witnessing significant growth, driven by various factors. The market dynamics are crucial in understanding the current and future trends in the Cancer (Tumor) Profiling market size and growth forecast.

Growth Drivers2 items

Increasing prevalence of cancer and the need for personalized medicine are driving the demand for Cancer (Tumor) Profiling, leading to a substantial growth forecast in the Cancer (Tumor) Profiling market size.

Advancements in genomic sequencing technologies and bioinformatics tools are enabling accurate and efficient Cancer (Tumor) Profiling, further fueling the growth of the Cancer (Tumor) Profiling market.

Restraints2 items

High cost of Cancer (Tumor) Profiling tests and reimbursement issues are limiting the adoption of these tests, thereby restraining the growth of the Cancer (Tumor) Profiling market size.

The complexity of Cancer (Tumor) Profiling data analysis and interpretation is a significant challenge, hindering the widespread adoption of Cancer (Tumor) Profiling in clinical practice.

Opportunities2 items

The increasing adoption of liquid biopsy tests and non-invasive Cancer (Tumor) Profiling methods is expected to create new opportunities for growth in the Cancer (Tumor) Profiling market.

The growing focus on precision medicine and immunotherapy is driving the demand for Cancer (Tumor) Profiling, leading to a significant growth forecast in the Cancer (Tumor) Profiling market size.

Challenges2 items

The standardization of Cancer (Tumor) Profiling tests and regulatory frameworks is a significant challenge, affecting the growth of the Cancer (Tumor) Profiling market size and growth forecast.

The integration of Cancer (Tumor) Profiling data with electronic health records and clinical decision support systems is a major challenge, requiring significant investment in informatics infrastructure.

Market Segmentation

Loading chart…

The Application segment in the Cancer (Tumor) Profiling market refers to the various uses of tumor profiling technologies, including diagnostics, research, and personalized medicine. This segment is crucial in understanding the Cancer (Tumor) Profiling segmentation, as it helps identify the primary areas where these technologies are applied. The diagnostics application holds a significant share of the market, driven by the increasing demand for accurate and reliable diagnostic tests.

The Types segment in the Cancer (Tumor) Profiling market encompasses various subtypes, such as [genetic profiling, proteomic profiling, metabolic profiling]. Each subtype contributes to the overall market size, with genetic profiling being the largest contributor due to its widespread adoption in cancer research and diagnostics. Understanding the market taxonomy of these subtypes is essential for industry players to navigate the complex landscape of Cancer (Tumor) Profiling.

Cancer (Tumor) Profiling Segmentation Breakdown8 items

Application

Clinical

Research

Types

Immunoassay

NGS

Mass Spectrometry

Others

Regional Insights

Loading chart…

The Cancer (Tumor) Profiling market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption of advanced technologies, favorable policies, and significant investments in cancer research. The region's mature infrastructure and established ecosystem also contribute to its dominant position.

Asia Pacific is the fastest-growing region, with a regional forecast indicating a significant increase in Cancer (Tumor) Profiling market growth, driven by factors such as a large and growing demographics, increasing infrastructure development, and rising ecosystem maturity. Europe, on the other hand, is driven by factors such as high adoption of precision medicine, favorable policies, and significant investments in cancer research. Latin America and Middle East & Africa are also expected to contribute to the market growth, driven by factors such as increasing adoption of advanced technologies and growing infrastructure development.

Key Drivers by Region5 items

North America: high adoption of advanced technologies, favorable policies, significant investments in cancer research

Europe: high adoption of precision medicine, favorable policies, significant investments in cancer research

Asia Pacific: large and growing demographics, increasing infrastructure development, rising ecosystem maturity

Latin America: increasing adoption of advanced technologies, growing infrastructure development

Middle East & Africa: increasing adoption of advanced technologies, growing infrastructure development

Competitive Landscape

The Cancer (Tumor) Profiling market is moderately consolidated, driven by a mix of global players and local/regional companies. The Cancer (Tumor) Profiling competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players are focusing on expanding their product portfolios and strengthening their distribution networks, while local companies are concentrating on regional expansion and customization.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are implementing various strategies to stay competitive:

Illumina: innovation pipeline

Qiagen: regional expansion

Neogenomics Laboratories: premium pricing

HTG Molecular Diagnostics: OEM tie-ups

Genomic Health: vertical integration

Caris Life Sciences: local manufacturing

Key Cancer (Tumor) Profiling Companies10 items

Illumina

Qiagen

Neogenomics Laboratories

HTG Molecular Diagnostics

Genomic Health

Caris Life Sciences

Helomics Corporation

Nanostring Technologies

Oxford Gene Technology

Ribomed Biotechnologies

Market Ecosystem

The Cancer (Tumor) Profiling ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. Value creation begins with technology providers and suppliers, who develop and provide essential components and services. These are then integrated by system providers and manufacturers, before being distributed through various channels to end users, including research institutions, hospitals, and pharmaceutical companies. The ecosystem's value chain analysis reveals a complex interplay of participants, each contributing to the development, marketing, and delivery of cancer profiling solutions.

Technology providers — develop diagnostic technologies

System integrators / EPCs — integrate profiling systems

Distributors / channel partners — supply products to end users

Service providers / after-sales — offer maintenance and support

End users / buyers — utilize profiling solutions for research and treatment

Regulators/standards bodies — establish guidelines and approvals

Data/analytics providers — provide insights for informed decision-making

The flow of value within the Cancer (Tumor) Profiling ecosystem is influenced by various control points, including regulatory approvals, technological advancements, and partnerships between participants. Dependency risks, such as input constraints and standards, can impact the adoption of profiling solutions. Furthermore, switching costs, interoperability requirements, and regional differences in healthcare infrastructure and regulations can also affect the ecosystem's dynamics. As the ecosystem continues to evolve, understanding these factors will be crucial for participants to navigate the complex landscape and capitalize on emerging opportunities.

Recent Industry Insights

The Cancer (Tumor) Profiling industry trends have witnessed significant developments over the last 12-18 months. Notably, there have been several strategic partnerships, such as collaborations between pharmaceutical companies and research institutions, aimed at advancing personalized medicine and improving patient outcomes. Additionally, the industry has seen a surge in mergers and acquisitions, with major players expanding their portfolios and capabilities in cancer profiling. Recent product launches and technological advancements, including next-generation sequencing and artificial intelligence-based diagnostic tools, have also transformed the landscape. Furthermore, regulatory changes and an increase in funding rounds have propelled innovation and growth in the Cancer (Tumor) Profiling market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Cancer (Tumor) Profiling market. The market attractiveness is driven by the increasing demand for personalized medicine and the need for accurate diagnosis. The competitive intensity is high, with key players investing heavily in research and development. The long-term outlook for the Cancer (Tumor) Profiling market outlook is promising, with a growing focus on innovation and technological advancements. However, the demand-supply balance is a key risk factor, as the market is highly dependent on the availability of skilled professionals and advanced equipment.

11 items

1. Executive Summary

2. Cancer (Tumor) Profiling Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cancer (Tumor) Profiling Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Cancer (Tumor) Profiling Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical

6.1.2. Research

6.2. Global Cancer (Tumor) Profiling Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunoassay

6.2.2. NGS

6.2.3. Mass Spectrometry

6.2.4. Others

6.3. Global Cancer (Tumor) Profiling Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Cancer (Tumor) Profiling Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cancer (Tumor) Profiling Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Cancer (Tumor) Profiling Market Competition by Key Manufacturers

8.1. Global Cancer (Tumor) Profiling Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Cancer (Tumor) Profiling: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Illumina

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Qiagen

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Neogenomics Laboratories

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. HTG Molecular Diagnostics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Genomic Health

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Caris Life Sciences

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Helomics Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Nanostring Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Oxford Gene Technology

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ribomed Biotechnologies

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cancer (Tumor) Profiling Market

Figure 4: Global Cancer (Tumor) Profiling Market: Drivers

Figure 5: Global Cancer (Tumor) Profiling Market: Challenges

Figure 6: Global Cancer (Tumor) Profiling Market: Trends

Figure 7: Global Cancer (Tumor) Profiling Market: Opportunity

Figure 8: Global Cancer (Tumor) Profiling Market: Restraint

Figure 9: Global Cancer (Tumor) Profiling Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Cancer (Tumor) Profiling Market Value (USD Million) By Region

Figure 15: Global Cancer (Tumor) Profiling Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Cancer (Tumor) Profiling Market Value (USD Million) By Region

Figure 23: Global Cancer (Tumor) Profiling Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Cancer (Tumor) Profiling Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Cancer (Tumor) Profiling Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Cancer (Tumor) Profiling Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Cancer (Tumor) Profiling Market Value (USD Million) By Region

Table 10: Global Cancer (Tumor) Profiling Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Cancer (Tumor) Profiling Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Cancer (Tumor) Profiling Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Cancer (Tumor) Profiling Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Illumina Basic Information And Sales Area

Table 31: Illumina. Products Portfolio

Table 32: Qiagen Basic Information And Sales Area

Table 33: Qiagen. Products Portfolio

Table 34: Neogenomics Laboratories Basic Information And Sales Area

Table 35: Neogenomics Laboratories. Products Portfolio

Table 36: HTG Molecular Diagnostics Basic Information And Sales Area

Table 37: HTG Molecular Diagnostics. Products Portfolio

Table 38: Genomic Health Basic Information And Sales Area

Table 39: Genomic Health. Products Portfolio

Table 40: Caris Life Sciences Basic Information And Sales Area

Table 41: Caris Life Sciences. Products Portfolio

Table 42: Helomics Corporation Basic Information And Sales Area

Table 43: Helomics Corporation. Products Portfolio

Table 44: Nanostring Technologies Basic Information And Sales Area

Table 45: Nanostring Technologies. Products Portfolio

Table 46: Oxford Gene Technology Basic Information And Sales Area

Table 47: Oxford Gene Technology. Products Portfolio

Table 48: Ribomed Biotechnologies Basic Information And Sales Area

Table 49: Ribomed Biotechnologies. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Cancer (Tumor) Profiling Market Value (USD Million) By Region

Table 55: Global Cancer (Tumor) Profiling Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cancer (Tumor) Profiling Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Illumina; Qiagen; Neogenomics Laboratories; HTG Molecular Diagnostics; Genomic Health; Caris Life Sciences; Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options